TriSalus Life Sciences (NASDAQ:TLSI) Rating Increased to Strong-Buy at Roth Capital

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at Roth Capital to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Several other analysts also recently commented on the stock. Northland Securities initiated coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 target price for the company. Roth Mkm initiated coverage on TriSalus Life Sciences in a research note on Monday. They set a “buy” rating and a $11.00 target price on the stock. Oppenheimer began coverage on TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target for the company. Finally, Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $12.25.

TriSalus Life Sciences Stock Up 5.9 %

NASDAQ:TLSI opened at $4.48 on Monday. TriSalus Life Sciences has a 12-month low of $3.32 and a 12-month high of $10.42. The firm has a market capitalization of $136.60 million, a price-to-earnings ratio of -1.79 and a beta of 0.49. The stock’s 50 day moving average price is $4.41 and its two-hundred day moving average price is $5.94.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The company had revenue of $7.36 million during the quarter. Equities research analysts expect that TriSalus Life Sciences will post -1.51 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Mary T. Szela acquired 7,520 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average cost of $5.20 per share, with a total value of $39,104.00. Following the completion of the purchase, the chief executive officer now directly owns 377,382 shares of the company’s stock, valued at $1,962,386.40. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Several large investors have recently bought and sold shares of the company. Duquesne Family Office LLC increased its stake in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares during the period. Highbridge Capital Management LLC acquired a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $1,184,000. Finally, Wolverine Asset Management LLC bought a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $240,000. 2.58% of the stock is currently owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.